31 C
Vientiane
Wednesday, September 3, 2025
spot_img
Home Blog Page 131

MDIS Opens Conversation on Part-Time Education and Its Challenges in Upcoming Fireside Chat

SINGAPORE, Aug. 21, 2025 /PRNewswire/ — The Management Development Institute of Singapore (MDIS) will be hosting a fireside chat titled “Part-Time, Full Impact: A Conversation on Work, Life, and Part-Time Studies” on 30 August 2025. This fireside chat is designed to offer working professionals practical insights into balancing part-time studies with full-time work and personal responsibilities.

Insights From Those Who’ve Done It

As more mid-career professionals in Singapore seek to stay relevant in a changing job market, flexible and skills-based learning options have become increasingly important. However, many adult learners still face significant challenges, such as managing time between work, family, and studies, as well as overcoming self-doubt.

This upcoming chat will bring together MDIS alumni and faculty members who have either experienced or supported such learning journeys. Panellists include:

  • Max Eng, alumnus of the Bachelor of Arts (Hons) Airline and Airport Management (Top-up), from Teesside University, UK
  • Karice Choo, alumna of the Bachelor of Arts (Hons) Business and Management (Top-up), from the University of Sunderland, UK
  • Qamarzeb Aurangzeb, Programme Manager (Tourism and Hospitality), from MDIS

Together, they will share personal insights into managing these common struggles. The fireside chat will also cover career transition stories and strategies for returning to school after time away, with practical tips on time management, staying motivated, and adapting to academic expectations.

Flexible Options for Working Professionals

The upcoming event will also highlight how MDIS’s part-time degree programmes are structured to help support not just academic growth but also career development. Designed with working adults in mind, these courses align with industry needs and allow learners to apply their skills directly in the workplace.

Alongside the fireside chat, MDIS is also offering ongoing benefits for participants who sign up for selected MDIS part-time degree courses in Singapore. This includes scholarship grants as well as a voucher giveaway, further supporting applications’ transition back into education.

Those interested in attending the event or exploring flexible education options can visit www.mdis.edu.sg/part-time-full-impact-fireside-chat-lp for more information and registration details.

About MDIS

The Management Development Institute of Singapore (MDIS), established in 1956, is a private education institution (PEI) that offers preparatory courses, diplomas, and degree programmes in partnership with universities from the United Kingdom and the United States. As a not-for-profit professional institute, MDIS provides academic pathways in various disciplines, with options available for both full-time students and working adults seeking part-time study.

 

CNA offers “paid media release” service in partnership with Media OutReach Newswire


SINGAPORE – Media OutReach Newswire – 21 August 2025 – CNA, the global news and current affairs brand of Mediacorp, is offering a new service which allows businesses and brands from around the world to seamlessly publish their media releases in a dedicated section on its flagship website, cna.asia, via its very first partner, Media OutReach Newswire.

Screengrab of paid media releases page on CNA

This new third-party paid content service offers businesses unprecedented access to one of the most trusted news platforms in Asia. Ms Jennifer Kok, founder and Chief Executive Officer of Media OutReach, said: “It is an honour to be the first newswire partner as CNA launches its new third-party content service. This partnership shows that the investment we have undertaken to deliver corporate news releases from public relations and investor relations professionals, and government bureaus across the Asia Pacific region has garnered recognition from the media. Based on data from Similarweb, we know that the highest readership can be attributed to local media, thus our focus will continue to be on forming content partnerships with local media in Southeast Asia, ASEAN, APAC, Africa, Middle East and globally.”

Commenting on the new media release distribution service, Mr Yong Chung Jin, Head of Business Operations at CNA, said: “This service is separate from our editorial operations. It is a partnership which will allow corporates and newsmakers a unique opportunity to showcase their latest developments and amplify their visibility by leveraging on CNA’s strong presence online to reach its highly engaged audiences around the world.”

Since its launch in 1999, CNA has evolved into a global news brand reaching audiences around the world with its award-winning range of content from breaking news to documentaries and current affairs programmes. Its website, cna.asia, attracts more than 90 million page views, and nearly 12 million unique visitors each month (Adobe Analytics, Jan-Jul 2025).

All published media releases on https://www.channelnewsasia.com/media-releases will be reproduced as they are received, with no revisions or edits by CNA. For more information, please visit https://www.channelnewsasia.com/media-releases.

Hashtag: #Mediacorp #CNA #MediaOutReachNewswire #pressrelease

The issuer is solely responsible for the content of this announcement.

About CNA

CNA was established in March 1999 by Mediacorp, and is an English language Asian news network. Positioned to “Understand Asia”, it reports on global developments with Asian perspectives. Based in Singapore, it has correspondents in major Asian cities and key Western ones, including New York, Washington D.C., London and Brussels. CNA brings its audience not only the latest news but also diverse content such as business, lifestyle, human stories, current affairs and documentary programming.

CNA is a transmedia company, where users can get content online, on TV and radio and via smart devices. It is also available on social and messaging services, such as , , , , and .

CNA has been recognised as Channel of the Year by the Association for International Broadcasting (AIB), the global trade association for broadcast journalism.

CNA TV is now viewed in 29 territories across Asia with its satellite footprint stretching across Asia, the Middle East and Australia.

For more information, please visit CNA’s website at .

About Mediacorp

Mediacorp is Singapore’s national media network and largest content creator, engaging 99 percent of the population weekly across four languages on its digital, TV, radio, and social media platforms. The company prides itself on creating compelling and trusted content that connects communities and inspires people.

Beyond Singapore, Mediacorp reaches a global audience through its award-winning news service, CNA, and globally distributed content that has won numerous industry accolades, including from the New York Festivals, World Media Festivals, PromaxBDA (World and Asia), and the Asian Academy Creative Awards.

As the nation’s media network, Mediacorp champions the diverse pool of local talent and the growth of the creative and media industry, through co-creation, partnerships and providing learning opportunities to groom the next generation of creators and media professionals.

For more information, please visit .

About Media OutReach Newswire

Founded in 2009, Media OutReach Newswire is Asia Pacific’s first global newswire founded and headquartered in Hong Kong with offices in China, Taiwan, Singapore, Malaysia, Thailand, Vietnam and Japan. The newswire comprehensive network of more than 200,000 editors and journalists, covering over 70,000 media titles, 1,500 media partners in more than 40 languages is an effective conduit between PR & IR professionals in agencies, companies and government bureaus.

As a total communications solution provider, Media OutReach Newswire leverages next-generation SaaS technology and AI to redefine press release distribution, delivering multimedia, multi-language press releases directly to journalists’ inboxes to optimise write-ups, build media relations and provides multi-format, ready to use reports with pioneering data insights and intelligence on Public Relations Campaign performance.

Media OutReach Newswire’s global press release distribution network that spans Asia Pacific & Southeast Asia, the USA, Canada, Latin America, Europe & UK, the Middle East & Gulf States, and Africa is a trusted newswire partner for PR and Communications Professionals from PR & IR agencies, corporations and governments for authentic communication results.

For more information about Media OutReach Newswire’s services and distribution network, please visit .

Blokees made its debut at 2025 Indonesia International Toys Expo , exhibiting multiple IP series new products

SHANGHAI, Aug. 21, 2025 /PRNewswire/ — From August 20 to 22, 2025, the Assembly Character Toys brand Blokees made its debut at the 2025 Indonesia International Toys Expo. Blokees exhibited over 50 model kits that are based on world-renowned IPs such as Ultraman, Transformers, Naruto, Minions, and Hero Infinity. In addition, nearly ten new model kits made their global debut on display.


With its rich and diverse product lineup, Blokees effectively meets the needs of players across a wide range of age groups and preferences. The booth attracted substantial interest from distributors and quickly became one of the highlights of the entire event.

Blokees’ new product was filled with highlights. Its Minions Mokoo Series 02: Summer Bello made its world debut at the exhibition, featuring six characters that embody the essence of a summer atmosphere. Stuart and Phil are depicted holding ukuleles, while Bob and Carl sport swimming rings. Kevin and Dave, transformed into tourists, are dressed in sunglasses, beach shorts, garlands, and water cups—offering an unexpected delight to devoted Minions fans.

Blokees’ Transformer Defender Version Series Devastator became the focus of the event due to its innovation. As the first combiner character in the history of the Transformers IP, the Blokees’ R&D team, through multiple rounds of optimization, faithfully captured the character form of Devastator. Players only need to collect all six Digger Team vehicle products from the Blokees’ Transformer Defender Version Series 01, 02, and 03 to exchange for the “Devastator Pack” and easily achieve Devastator. Behind this innovation is Blokees’ robust R&D system, supported by over 500 patents, underscoring the brand’s strong innovation capabilities and core competitive edge.

In addition to its diverse product lineup, Blokees is enhancing regional engagement through BFC culture. At the exhibition, Blokees exhibited BFC works from Indonesian BFC creators, demonstrating a profound co-creation between the brand and its users.

Through its “Universally appealing;Stepwise pricing;Globally promoting” strategy, Blokees has achieved significant breakthroughs in multiple international markets, including Southeast Asia, Europe, North America, and Latin America. Blokees is promoting Chinese Assembly Character Toys onto the global stage.

Toshiba and naturenix Scale Up and Transition to Paid Battery Subscription Pilot for E-Motorcycle Taxis in Bangkok

— Advancing a Sustainable Manufacturing Business Model —

KAWASAKI, Japan and TOKYO, Aug. 21, 2025 /PRNewswire/ — Toshiba Corporation and battery-tech startup naturenix inc. are taking their battery subscription demonstration test for electric motorcycle taxis in Bangkok, Thailand, to the next level by expanding the scale and shifting to a paid subscription model. Both companies are now preparing for the transition, and production of battery packs and related components has started. The new phase will run from December 2025 through March 2026.

Toshiba and naturenix
Toshiba and naturenix

From September 2024 to March 2025, the two companies conducted the first phase of service testing free of charge, allowing motorcycle taxi drivers to quickly swap battery packs at a dedicated charging station and return to carrying passengers*1. In this trial, Toshiba supplied its SCiB™ lithium-ion batteries, while naturenix developed battery packs and chargers and modified the motorcycles. Sensors embedded in the motorcycles collected data on ambient temperature, environmental conditions, and driver behavior. The results, alongside driver surveys, confirmed the long-life and reliable performance of SCiB™, even in the torrid heat of Bangkok, and validated naturenix’s core technologies.

The paid service will be larger in scale, supporting up to 100 electric motorcycles, and one charging station will become five, covering Bangkok and its environs. Toshiba will continue to supply SCiB™ batteries, and naturenix will provide its proprietary system, a solution for rapid charging with standard power outlets. To refine the service, the two companies will leverage Thailand’s Windee International*2 to gather feedback from drivers, including their reactions on pricing. They will also identify technical challenges resulting from scaling up production, evaluate the performance of the new charging technology, and analyze battery degradation while exploring potential countermeasures.

The battery packs for the second round of testing are upgraded and improved, with real-time monitoring of usage history and cell-level degradation, coordinated control across multiple packs, and optimized management for rapid charge/discharge cycles. Designed for reuse and repurposing in second-life applications, the new packs will contribute to development of a circular electrification ecosystem that maximizes resource use and reduces disposal-based recycling.

Toshiba and naturenix position the service as the proving ground for a new business model. In response to growing environmental concerns and the resource depletion associated with mass production and consumption, the two companies are advancing a sustainable business model centered on long-life batteries and subscription-based services. This approach challenges the traditional “volume equals revenue” paradigm by prioritizing durability over disposability, and aims to realize a more sustainable manufacturing framework.

Following the second round of demonstration testing, Toshiba and naturenix plan to launch a commercial subscription service for motorcycle taxi drivers in fiscal year 2026, and look to future expansion into industrial applications such as forklift trucks. Over the long term, Toshiba and naturenix will advance the integration of mobility and energy infrastructure as a unified service, aiming to expand both its applications and business scope.

*1 Toshiba and Naturenix Launch Demonstration Test of Battery Subscription Service for Electric Motorcycle Taxis in Bangkok

*2 naturenix’s joint venture with a local parking management service provider.

About Toshiba

In 2025, the Toshiba Group celebrates its 150th anniversary. As the company looks ahead, it is enhancing its management structure, streamlining operations, and investing in forward-looking businesses to build foundations for new growth. This will allow it to continue to support advances toward a sustainable future with products and services developed by its wide range of businesses in the energy, infrastructure, and electronic devices domains.

Guided by its corporate philosophy, “Committed to People, Committed to the Future.,” Toshiba brings industry-leading capabilities in green transformation (GX) and digital transformation (DX) to solutions for companies addressing the many challenges faced by modern society. By leveraging the power of data derived from its constantly evolving products and solutions, the Group is determined to help to achieve carbon neutrality and a circular economy.

In fiscal year 2024, Toshiba Group recorded annual sales of 3.5 trillion yen and employed 95,000 people worldwide. For more information, visit our website or follow us on LinkedIn.

About naturenix

naturenix is a start-up company that aims to create a world where nature and electronics coexist through the provision of battery longevity technologies and next-generation energy platforms. By collecting dynamic data on batteries in actual use and analyzing it with AI technology, the company promotes open innovation in batteries and ensures long-term use across multiple applications by guaranteeing asset value based on an understanding of battery use and degradation. For more information, please visit https://www.naturenix.co.jp/en/index.html

Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth

MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise.

H1 2025 key results[1]

Group performance[2]: Reflects strategic investment for long-term value creation

  • Revenue of $390.4 million, up by 63%[3] and on track to meet full year guidance[4].
  • Group gross profit margin of 53% reflects product mix change to include third-party RLS sales. Illuccix® margin remains stable.
  • Adjusted EBITDA[5] of $21.1 million, reflective of increased operating expenditure driven by strategic acquisitions, investment in commercial infrastructure, and research and development (R&D) investment.
  • $81.6 million invested into R&D, a 47% increase year-over-year. Investment was primarily focused on late-stage assets in the therapeutics and precision medicine pipeline. Full year R&D investment guidance is maintained[6].
  • Loss before tax of $4.8 million includes $12.4 million in non-cash finance costs associated with convertible bonds issued in July 2024 and increased amortization cost of $9.5 million (2024 $2.4 million) following RLS acquisition.
  • Positive operating net cash flow of $17.7 million, cash balance $207.2 million following $241. 8 million of strategic merger and acquisition (M&A) investment.

Telix Precision Medicine: Commercial business delivers profitable growth

  • Precision Medicine segment revenue up by 30% compared to H1 2024, driven by continued increase in Illuccix dose volumes.
  • Illuccix gross margin remains stable at 64%.
  • Adjusted EBITDA up by 24% year-over-year to $104.6 million.
  • Selling and marketing expenses of $40.9 million, reflecting incremental investment in commercial infrastructure for new product launches (Illuccix European launches and Gozellix®, Zircaix® and Pixclara®[7]).

Telix Manufacturing Solutions (TMS): Investment in infrastructure to scale operations and meet future demand

  • TMS segment includes RLS Radiopharmacies (RLS, U.S.[8]), IsoTherapeutics (TX, U.S.), and TMS facilities in Sacramento (CA, U.S.), Brussels South (Belgium), North Melbourne (Australia) and Yokohama (Japan), representing a significantly augmented global production and manufacturing footprint to support clinical and commercial operations.
  • Operating expenses of $30.5 million for the segment include $14.9 million for RLS business and $15.6 million to support start-up and integration activities (ex-RLS).
  • RLS – the core revenue driver in TMS – reported $109.5 million of revenue, which includes $79.0 million from third-party PET[9] and SPECT[10] product sales and distribution service fees, and $30.5 million inter-segment revenue.
  • RLS delivered an Adjusted EBITDA loss of $1.1 million.
  • RLS operating loss includes $6.3 million of depreciation and amortization.

Telix Therapeutics: Reinvesting earnings to accelerate late-stage pipeline

Of the total R&D investment, 54% ($43.9 million) was invested in the therapeutics pipeline. Milestones achieved include:

  • TLX591 (177Lu-rosopatamab tetraxetan): Completed target enrollment of 30 patients for Part 1 of the Phase 3 study in advanced metastatic castration resistant prostate cancer (mCRPC). The trial has received regulatory approval to proceed in Australia, China, Canada, New Zealand, Turkey and Japan.
  • TLX592 (225Ac-PSMA-RADmAb): Approval to commence a Phase 1, first-in-human therapeutic study of a targeted alpha therapy in advanced mCRPC.
  • TLX101 (131I-iodofalan, or 131I-IPA): Approval to commence IPAX BrIGHT, an international pivotal trial, to commence at Australian sites initially.
  • TLX090 (153Sm-DOTMP): Investigational New Drug (IND) application approved for a Phase 1 bridging study for Telix’s therapeutic candidate for the palliation of bone pain in patients with osteoblastic metastatic disease to the bone.

Commentary

Managing Director and Group CEO, Dr. Christian Behrenbruch, commented on the result:

“Telix continues to deliver strong revenue growth while building a foundation for the future. The first half of 2025 was a period of rapid transformation as we expanded our global manufacturing operations, invested in launching new products in new markets, and accelerated the development of our therapeutic pipeline. These investments have positioned Telix for sustainable, long-term growth, while our diversified business provides multiple drivers of success. To generate future revenue growth, we are confident in securing product approvals for Pixclara and Zircaix while advancing geographic and indication expansion for the PSMA portfolio.”

Summary Group financial results

H1 2025

H1 2024

US$M

US$M

Revenue

390.4

239.6

Cost of sales

(181.8)

(82.4)

Gross profit

208.6

157.2

Research and development (R&D)

(81.6)

(55.4)

Selling and marketing

(49.0)

(24.6)

Manufacturing and distribution

(18.8)

(8.4)

General and administration

(47.7)

(39.2)

Other losses (net)

(1.1)

(1.9)

Operating profit

10.4

27.7

Finance income

3.6

0.9

Finance costs

(18.8)

(5.7)

(Loss)/profit before tax

(4.8)

22.9

Adjusted EBITDA

21.1

37.1

Cash from operating activities

17.7

23.3

Guidance

  • Telix confirms FY 2025 revenue guidance of US$770 million to US$800 million[11].
  • Guidance reflects revenue from Illuccix sales in jurisdictions with a marketing authorization, and 11 months of revenue contribution from RLS[12].
  • Telix confirms R&D expenditure guidance, expecting a year-over-year increased investment range for FY 2025 of 20% to 25% compared to FY 2024.

lnvestor call

An investor webcast and conference call will be held at 9.30am AEST on Thursday 21 August 2025 (7.30pm EDT Wednesday 20 August 2025).

Participants can register for the webcast by clicking here: https://edge.media-server.com/mmc/p/x4gytx8w/ or the teleconference here: https://s1.c-conf.com/diamondpass/10049152-x745re.html

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Canada, Europe (Belgium and Switzerland), Brazil and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations (Global)
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)
Ms. Annie Kasparian
Telix Pharmaceuticals Limited
Director Investor Relations and Corporate Communications
Email: annie.kasparian@telixpharma.com

Guidance Disclaimer

The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements.

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country.

Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

[1]. See summary Group financial results table at end of this document.
[2]. Group performance includes Telix Precision Medicine, Telix Therapeutics and Telix Manufacturing Solutions (TMS).
[3]. All comparisons to H1 2024 results.
[4]. FY 2025 revenue guidance of US$770 million to US$800 million.
[5]. Earnings before interest, tax, depreciation and amortization.
[6]. Increased investment range for FY 2025 expected to be 20% to 25% compared to FY 2024.
[7]. Launch and brand names subject to final regulatory approval.
[8]. RLS network is comprised of 28 locations across the U.S.
[9]. Positron emission tomography.
[10]. Single photon emission computed tomography.
[11]. Refer to ASX disclosures 20 February 2025.
[12]. See Guidance Disclaimer for further information.

Solar distributor OSW secures $5.5 million USD to accelerate global expansion

Funding to fuel OSW’s U.S. expansion and tech platform rollout

SYDNEY, Aug. 21, 2025 /PRNewswire/ — OSW (One Stop Warehouse), Australia’s leading solar wholesaler and distributor, has secured $5.5 million USD in strategic funding from SparkEdge Capital, a top-tier venture capital firm based in Shanghai focused on the energy and technology sectors.

The path to global solar adoption

Founded in 2013, OSW has established itself as the market leader in Australia’s solar sector for over a decade, holding the market share for seven consecutive years. Internationally, the company has built a strong presence across Europe, particularly in the Netherlands and Poland, where it has achieved over 20% market penetration in select regions.

The new capital will fuel OSW’s next phase of international growth in key solar markets, including the United States, Mexico, Spain, and Romania. The funding will also accelerate the rollout of OSW’s proprietary technology platform, GreenSketch, which digitises and connects every stage of the clean energy value chain.

OSW Founder Anson Zhang stated, “We’ve led the Australian market for years – this investment marks a major milestone as we expand into new markets and continue developing the infrastructure needed to support the global energy transition. OSW is building an AI-driven distributed energy industry internet platform – our vision is to become the ‘Amazon’ of clean energy, delivering integrated solutions.”

This year, OSW launched GreenSketch – a platform that is set to revolutionise faster solar deployment and rollout. Greensketch is the world’s first end-to-end solar design platform that offers a zero-cost solution, integrating design, procurement, subsidy applications, and project management in one free-to-use interface.

Backing the future of solar

“We were drawn to OSW’s unique ability to combine smart software with deep sector expertise,” said Bin Wang, Partner at SparkEdge Capital. “Tools like GreenSketch are setting a new standard for clean energy delivery – and we believe OSW is positioned to lead the next wave of global solar adoption.”

With the backing of SparkEdge Capital, OSW is focused on integrating AI-powered tools and automation into every layer of the solar journey – from system design and compliance, to credit scoring and carbon tracking. Strategic partnerships in each region will support local deployment and help scale OSW’s clean energy infrastructure worldwide.

For more information on OSW, please visit the website. For those ready to experience GreenSketch, visit the website to sign up and start designing for free.

DigiFT Closes Strategic Round to Scale Institutional-Grade RWA Infrastructure, Securing US$25 Million to Date

SINGAPORE, Aug. 21, 2025 /PRNewswire/ — DigiFT, a licensed exchange purpose-built for institutional-grade, tokenized real-world assets (RWAs), today announced it has raised a total of US$25 million to date—following the close of a new strategic funding round. The latest round was led by SBI Holdings, Japan’s largest financial group, with participation from leading institutional investors including Mirana Ventures, Offchain Labs (Arbitrum), Yunqi Partners, Polygon Labs, and founders and senior leaders of leading global technology and financial firms.

The capital will support DigiFT’s continued expansion as a next-generation RWA infrastructure provider—bridging traditional asset management and onchain finance through compliant, tokenized investment products. As a licensed exchange, DigiFT not only facilitates the trading and distribution of institutional-grade RWAs but also enhances their secondary market liquidity and on-chain utility, driving greater capital efficiency and expanding yield access for both institutional and Web3-native participants.

Leading the round is SBI Holdings—a Japanese financial conglomerate with a broad presence across the digital asset and blockchain sectors. Known for early investments in companies such as Ripple and R3, SBI also operates a wide range of businesses spanning securities, banking, asset management, and crypto infrastructure, with a long-standing track record in fintech and capital markets innovation globally.

“DigiFT has the regulatory discipline, product maturity, and focus on real onchain utility to lead the convergence of traditional finance and Web3,” said Yoshitaka Kitao, Representative Director, Chairman, President & CEO, SBI Holdings. “What sets them apart is their focus on enabling real onchain utility for institutional-grade assets—going beyond tokenization to unlock collateral use cases, embedded yield, and secondary market liquidity. This pragmatic approach to infrastructure aligns with the needs of institutional investors, and we’re proud to support their growth across Asia and globally.”

Strategic Use of Funds

The funding will accelerate DigiFT’s next phase of growth, with key areas of focus including:

  • Product Diversification – Expanding its portfolio of tokenized investment strategies across equities, fixed income, alternatives, and digital assets
  • Innovation & Research – Developing new on-chain use cases for tokenized RWAs to unlock broader utility across digital finance ecosystems—spanning Web3, payments, and other on-chain ecosystems
  • Builder Enablement – Driving greater interoperability and capital efficiency via smart contract-based infrastructure, while ensuring compliance with the standards required by financial institutions and Web3 participants.

“This raise validates the institutional momentum behind tokenized finance—and DigiFT’s unique role in driving it forward,” said Henry Zhang, Founder & Group CEO of DigiFT. “We’re honored to be backed by both leading TradFi players and top-tier Web3 investors. Together, we’re building an open, interoperable capital markets infrastructure for the on-chain economy.”

Real-World Assets, On-Chain Utility

DigiFT enables traditional asset managers to reach new investor bases, while empowering crypto-native users to access institutional-grade investment strategies across money markets, public mutual funds, U.S. Treasuries, and private credit. Leading asset managers on the platform today include Invesco, UBS Asset Management, CMB International Asset Management, and Wellington Management.

The platform has also brought more diversified strategies on-chain, including the Peakwater Volatility Alpha Fund token (pEAK)—the first institutional-grade tokenized volatility strategy targeting cross-asset volatility returns across traditional and alternative markets.

Beyond tokenization, DigiFT has enabled new on-chain utility for institutional-grade RWAs—most notably making them eligible as high-grade collateral on digital asset exchanges for active trading and embedding RWA yield directly within payments cards to bring on-chain returns into everyday transactions.

DigiFT was recently granted Type 1 and Type 4 licenses by the Hong Kong Securities and Futures Commission (SFC)—making it the first regulated platform for institutional-grade, tokenized RWAs to be licensed by both the SFC and the Monetary Authority of Singapore (MAS), two of Asia’s most sophisticated financial regulators.

Media Contact
media@digift.io 

About DigiFT

DigiFT is a next-generation exchange for tokenized real-world assets (RWAs), licensed by the Monetary Authority of Singapore (MAS) and the Hong Kong Securities and Futures Commission (SFC). The platform offers end-to-end digital asset services—including tokenization, issuance, distribution, trading, and instant liquidity provision—purpose-built for institutional RWAs. Trusted by global financial institutions, DigiFT is the on-chain tokenization and distribution partner for leading asset managers such as Invesco, UBS Asset Management, CMB International, and Wellington Management. To learn more, visit www.digift.io.

Disclaimer: DigiFT and/or its affiliates endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon information contained on this article. This is not an advertisement making an offer or calling attention to an offer or intended offer. Before making any investment decision, please seek independent legal and financial advice. This document is distributed in Singapore only to Accredited Investors and Institutional Investors within the meaning of Securities and Futures Act 2001 and is not intended for investors who are not such accredited investors. DigiFT accepts no legal responsibility for the content of this article to other investors, which is not intended for them.  

Manhattan Associates promotes Raghav Sibal to lead APAC region amid continued growth

Expanded leadership follows 49% cloud growth and surging demand for AI-enabled supply chain solutions across Asia-Pacific

SYDNEY, Aug. 21, 2025 /PRNewswire/ — Manhattan Associates Inc. (NASDAQ: MANH) has promoted Raghav Sibal to Vice President, APAC, a newly expanded role that reflects the company’s commitment to supporting rising demand across the region. The move follows a standout year of growth, with cloud subscription revenue in APAC rising 49% year-on-year in 2024 and services revenue up 21%, reflecting the region’s growing appetite for cloud-first, AI-enabled supply chain solutions.

Raghav Sibal, Vice President, APAC, Manhattan Associates
Raghav Sibal, Vice President, APAC, Manhattan Associates

“Over the past 14 years, Raghav has played a pivotal role in establishing Manhattan Associates’ strong foundation and continued growth in Australia and New Zealand. With the APAC region undergoing rapid transformation and expansion, the time is right to elevate his role,” said Eric Clark, President and CEO at Manhattan Associates. “He brings the operational expertise, customer-first mindset and regional insight needed to accelerate our vision for unified supply chain commerce across Asia-Pacific.”

With more than two decades at Manhattan Associates, Sibal brings deep operational experience to the position, having worked across both the US and Australian markets, leading some of the company’s most complex global implementation programs. Since taking on leadership of the Australia and New Zealand business in 2011, he has overseen significant growth, built a high-performing local team, and helped position Manhattan as a trusted technology partner for leading retailers, distributors and logistics providers across the region.

“APAC is an incredibly diverse region, with each market presenting unique challenges and opportunities,” commented Sibal. “As supply chains continue to evolve and digital transformation accelerates, I’m excited to work closely with our teams, partners and customers across the region to help them unlock new levels of efficiency, resilience and customer experience.”

Manhattan Associates’ APAC operations service emerging opportunities in China, Southeast Asia, and India, as well as more established markets in Japan, Australia and New Zealand.

For more information about Manhattan Associates, visit www.manh.com.au. Receive up-to-date product, customer and partner news directly from Manhattan Associates on XLinkedIn and Facebook.

-ends-

ABOUT MANHATTAN ASSOCIATES

Manhattan Associates is a global technology leader in supply chain and omnichannel commerce. We unite information across the enterprise, converging front-end sales with back-end supply chain execution. Our software, platform technology and unmatched experience help drive both top-line growth and bottom-line profitability for our customers.

Manhattan Associates designs, builds, and delivers leading edge cloud and on-premises solutions so that across the store, through your network or from your fulfilment centre, you are ready to reap the rewards of the omnichannel marketplace. For more information, please visit www.manh.com